deltatrials

Dermatitis, atopic Trials in Fountain Valley, United States

Conditions / Dermatitis, atopic / Fountain Valley, United States

Dermatitis, atopic is a medical condition with active clinical research programs worldwide.

13 total trials for this combination

Showing top 10 of 13 trials

Trials

NCT ID Title Status Phase
NCT03627767 Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects COMPLETED PHASE3
NCT06130566 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis COMPLETED PHASE3
NCT06015308 A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo COMPLETED PHASE2
NCT06881251 A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) ACTIVE_NOT_RECRUITING PHASE2
NCT04800315 A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis COMPLETED PHASE2
NCT06407934 A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis ACTIVE_NOT_RECRUITING PHASE3
NCT03428646 Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) ACTIVE_NOT_RECRUITING —
NCT05999799 A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis TERMINATED PHASE2
NCT05492578 Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials ENROLLING_BY_INVITATION PHASE2/PHASE3
NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis COMPLETED PHASE3

Related Pages